Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia

Clinical trial NCT07538713 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07538713
Sponsor: Qi deng
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

CAR T Cell Therapy CD33 Positive Acute Myelogenous Leukemia

Start date: 2026-06-01
Primary completion: 2028-05-31
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.